Performance of ina nuclec acid yekukwikwidza emagetsi emahara kuti uzive vanochengetedza-cov-2 muEthiopia

Ndatenda nekushanya kwechiratidzo.com. Uri kushandisa bhurawuza shanduro ine mashoma CSS rutsigiro. Zvekuziva zvakanakisa, tinokurudzira kuti ushandise browser yakagadziridzwa (kana kudzima nzira yekuenzanisa muInternet Explorer). Mukuwedzera, kuve nechokwadi chekutsigirwa kuripo, tinoratidza nzvimbo yacho isina masitaera uye JavaScript.
Inoratidza carousel yemasiraidhi matatu kamwechete. Shandisa mabhatani ekutanga uye anotevera kuti afambe kuburikidza nematanho matatu panguva, kana shandisa mabhatani ekuseta pamagumo kuti afambe kuburikidza nematatu matatu panguva.
Sezvo iyo 2019 chirwere chegore Kunyangwe miedzo yakati wandei yakakurumidza kugadzirwa uye ishandiswe kumarabhoritari yekuongorora, iko kuita kweiyi bvunzo hakuna kuongororwa mumhando dzakasiyana siyana. Naizvozvo, ichi chidzidzo chakanangana nekuongorora mashandiro embudzi-cov-2, daan gete, bgi, uye surure biotech learts uchishandisa iyo composite Reference standard (crs). Chidzidzo ichi chakaitwa kuEtiopiya yeEtiopiya yeEtiopiya yeEtiopiya Of 164 fungidziro, 59.1% yaive yakanaka uye 40.9% vaive vasina kunaka kune crs. Surure Biotech Positivity yaive yakaderera zvakanyanya kuenzaniswa neCRS (P <0.05). Surure Biotech Positivity yaive yakaderera zvakanyanya kuenzaniswa neCRS (P <0.05). Положительые результаты Surure Biotech были сранетельно с Surure Biotech mhedzisiro yaive yakanyanya kuderera ichienzaniswa neCRS (P <0.05).与 Crs 相比, Surure Biotech 的阳性率显着较低 (P <0.05).与 Crs 相比, Surure Biotech 的阳性率显着较低 (P <0.05). У Sansure Biotech было зни тьньнььше половите Surure Biotech aive aine mashoma mashoma emhedzisiro achienzaniswa neCRS (P <0.05).Chibvumirano chemuzano chevana chevana chaive 96.3-100% ichienzaniswa neCRS. Kuwedzera kune yakaderera positivity mwero weiyo surure biotech assay, kuita kwemakona mana kwainge kwaitika. Nekudaro, iyo surure yeBiotech [Rwiyo rwekutsvagisa chete (Ruo)] Assay inoda imwe yekusimbiswa kwekushandisa kwayo muEthiopiya. Pakupedzisira, kutsvagisa kwekuwedzera kunofanirwa kuongororwa kuti kuongororwazve masals neakakodzera vagadziri veMugadziri.
Laboratori kuyedzwa chikamu cheWorld Health Organisation (ndiani) chirongwa chehurongwa hweCoronavirus chirwere 2019 (COVid-19) Kugadzirira uye mhinduro (Spring). Anopa zano kuti nyika dzinoda kuvaka kugona kwekushanda kwekuvandudza kugadzirira, nyaya yakakodzera yekutarisira, kusvinura uye nekukurumidza kupindura kwehutano hweveruzhinji. Izvi zvinoratidza kuti basa rerabhoritari rinokosha kuratidza chirwere uye chirwere chehurume hwevamiriri vane hutachiona uye vanodzora kupararira kwavo.
Kuongororwa kweChidvid-19 kunoda chirevo uye kurapwa ruzivo, zviratidzo zvemunhu / zviratidzo, uye radiographic uye radioratory data2. Sezvo kuwanda-kwa19 kubuda kwakaziviswa muWuhan, China, vazhinji vekutengesa nuclec acid yekukwikwidza (NATS) vakagadziriswa kutenderera pasirese. Real-Nguva Reverse Transcript Polymerase Chain Reaction Molecular Kuonekwa kweSurs-COV-2 inowanzoenderana neN (nuleocapsid protein genge), e Envelopu (rna-French gentese geymerase Gene) Dunhu Rinozivikanwa Kubva Kune Viral genome. Ivo vanoonekwa sevakachengetedzwa zvakakoshesa matunhu anowanikwa muhutachiona hwehutachiona hwehutachiona Pakati peaya majini, iyo yeRDRP uye EGES ine yakakwira analyticalice yekuona kunzwa, nepo n gene ine kuderera kuongororwa sensitivity5.
Iko kuita kwePCR fungidziro kunogona kusiyana zvichienderana nezvinhu zvakasiyana-siyana zvakadai se: Extract Repagents, kukwidziridzwa Reagents, mhando yeiyo pcr muchina uye zvimwe zviridzwa. Sezvinei muna Kubvumbi 2020, zvinopfuura 48 madhiri ekuongororwa 48 akasiyana kubva kunyika pfumbamwe akagamuchira emergency emergency mvumo (eua) yekubatira-196 dignostics. MuEthiopia, anopfuura 14 nguva PCR mapuroni anoshandiswa pane iyo PRR yekuonekwa kweCRS-COV-2 pa2 8500, Abbott M2000, Roche 48000 uye huwandu-studio7. Uye zvakare, dzakasiyana-siyana PRR bvunzo kits dziripo, dzakadai saDaan Genee test, Abbott anoyera-cov-2 bvunzo, surure bvunzo dzeBhaibheri, uye sing-cov-2 bvunzo. Kunyangwe rrt-plcr ari akanyanya kuterera, vamwe varwere vane mikana yekuverenga, mamiriro uye zviito zvevashandi. Uye zvakare, sampuro kana kudzora zvisizvo, kutenderera kwechikepe Nekudaro, zviri pachena kuti PRR bvunzo dzinogona kunyatsoziva vatakuri vezvidimbu zvejeri, sezvo vasingakwanise kusiyanisa pakati pevaenziyano vanonyatsoita, saka bvunzo dzinogona kungoona vatakuri uye kwete varwere10. Naizvozvo, zvakakosha kuongorora maitiro ekuongorora uchishandisa nzira dzakajairika mumamiriro edu. Kunyangwe akawanda eaat reagents inowanikwa kuEtiopiya yeEtiopiya yeEtiopiya yehutano hwehutano hwehutano Naizvozvo, ichi chidzidzo chakanangidzirwa kuongorora maitiro ekufananidza ebhenji rekutengeserana rekutengeswa kwekuonekwa kweanopinda-cov-2 ne rrt-pl-pcr uchishandisa clinical fungidzira.
VAKAWANDA vatori vechikamu 164 vaine munhu anofungidzirwa kuti anofungidzirwa-19 akaiswa muchidzidzo ichi. Ruzhinji rwemasampula rwacho rwaive kubva kunzvimbo dzekurapa (118/164 = 72%), nepo makumi mana neshanu (28%) vatori vechikamu vaibva kunzvimbo isiri yekurapa. Pakati pevatori vechikamu vasingabatwe kuCentre, 15 (9.1%) vakanga vafungidzirwa nemhosva uye 31 (18,9%) vaive vaonana nemhosva dzakasimbiswa. Makumi mapfumbamwe-matatu (56.7%) Vatori vechikamu vaive vechirume, uye zvinoreva (± SD) zera revatori vechikamu raive 31.10 (× 11.82) makore.
Muchidzidzo ichi, mwero wakanaka uye asina kunaka emiedzo ina yeiyo Chand-19 yaive yakatemwa. Nekudaro, iyo mwero wepazasi embudzi. Iyo yakanaka uye isina kunaka composite Reference standard (crs) zviyero zvaive 97 (59.1%) uye 67 (40.9%), zvakateerana (tafura 1). Muchidzidzo ichi, tsananguro yeCRS yaive yakavakirwa pa "chero" mutemo "wechiitiko, umo kunze kwemhedzisiro ina, miviri kana yakawanda mhedzisiro yakapa mhedzisiro yakafanana yakaonekwa sechokwadi kana yakaipa.
Muchidzidzo ichi, takawana chibvumirano chisina kunaka muzana (NPA) ye100% (95% CI 94.6-100) kune vese kuongororwa zvichienzaniswa neCRS. Ongororo yeiyo yeiyo yeiyo yeiyo yebhoti yekuongorora yakaratidza chidiki che93.8% (95% CI 87.297 Mukupesana, kuganhurana kwakazara pakati peanopfugiramu-cov-2 bgi assay uye sansure biotech 2019-ncov assay yaive 98.8% uye 96.3%, zvichiteerana (tafura 2).
Cohen's kappa coeff fifferction pakati peCRS uye Abbott anochengetedza-cov-2 assay mhinduro dzaive dzakanyatsoenderana (K = 1.00). Saizvozvo, kapapa's kappa tsika yakaonekwa naDaan gen Gene Mukufananidza uku, iyo chi-chi-chi-mrass test
Sezvinoratidzwa muPi.1 iyo muzana yeyakaderera ct kukosha (<20 ct) yeBabort Sers-2 Assay (NCEFT YEMAHARA YEMAHARA CT 1 iyo muzana yeyakaderera ct kukosha (<20 ct) yeBabort Sers-2 Assay (NCEFT YEMAHARA YEMAHARA CTSezvinoratidzwa muPi.1, процентьньньньньньньньньньньньньшего значения ct-COV-2 ( Biotech 2019-NCOV показало что 1, iyo muzana yeiyo yakaderera CT kukosha (<20 CT) yekuongorora Abbott Surs 3.2%.如图 1 所示, Abbott sar-cov-2 检测 (结合 rdrp 和 n 基因) 的最低 CT 值百分比 (<20 Ct 检测的 Orf1 Sezvakaratidzwa mumufananidzo 1, yakaderera ct kukosha kweCT muzana 3.2%. Как празано на ри abboн 1, аназ abbott sars значение Ct гена orf1a / b в исследовании Sansure Biotech 2019- анализ ncov показал низкий ct. Sezvinoratidzwa mumufananidzo 1, iyo Abbott sars-2 assay (inosanganisa iyo rdrp uye maCT) pa 87.6%, B Gene Процений (<20 ct) Составил 50,3%, а рокинт зысокина высокинай ct (36-40 ct) составил 3,2%. Iyo muzana yetsika (<20 ct) yaive 50.3%, uye muzana yeakakwirira CT kukosha (36-16 ct) yaive 3.2%.Iyo Abbott sars-cov-2 b bvunzo yakarekodwa ct kukosha pamusoro makumi matatu. Kune rimwe divi, paBGI Sars-COV-2 Assay Orf1a / B Ge Gumi yaive neyakanyanya CT kukosha (> 36 CT) muzana yaive 4% (Fig. 1). Kune rimwe divi, paBGI Sars-COV-2 Assay Orf1a / B Ge Gumi yaive neyakanyanya CT kukosha (> 36 CT) muzana yaive 4% (Fig. 1). С д с д с г а а и и Г - Г Г Г Г Г «Г Kune rimwe divi, mukuongorora kweBGI Sars-COV-2 gene ORF1A / B yaive neyakakwira CT kukosha (> 36 CT)另一方面, 在 BGI Sars-COV-2 检测中, ORF1A / B 基因具有高 CT 值 (> 36 CT)】 4% (图 1). Kune rimwe divi, muBGI Sars-COV-2 Kuongororwa, iyo Internce of Orf1a / B Gumi ine Yakakwira CT Kukosha (> 36 CT) ndeye 4% (Mufananidzo 1). С д с а с с и и Аназе bgi sars-cov-2 процент генов orf1a / b с с с Г Г Г Kune rimwe divi, muBGI Sars-COV-2 kuongorora, iyo muzana ye orf1a / b majini ane huwandu hweCT (> 36 ct) yaive 4% (Fig. 1).
Muchidzidzo ichi, takatora 164 Nasophaysngeal samples. Kune ese marudzi emasaini, rna kuzviparadzanisa uye kukwikwidza kwakaitwa uchishandisa nzira uye kits yakakurudzirwa nevanogadzira vagadziri.
Chidzidzo ichi chakaratidza kuti bvunzo dzaAbbott weSers-COV-2 ine chiitiko chakafanana chekuona secrs, ne 100% yakanaka, isina kunaka, uye yakazara concordance. Chibvumirano chaCappa cheCAPTA chiri 1.00, zvichiratidza chibvumirano chizere neCRS. Kudzidza kwakafanana neYunivhesiti yeWashington muSin . Chidzidzo cheVienna, Austria yakaratidzawo kuti kurudziro huru yemuenzaniso uye kuona huwandu hwevanhu vazhinji vakadzora madhiri uye kuwanikwa kwekuona kwaakanaka13. Saka, mutambo wakakwana waAbhifotsi weSers-Cov-2 Assay unogona kuve wakabatana nePlatform System iyo yakafanana majisitori yerudzi,
Mhedzisiro yedu yakaratidzawo kuti kuita kwekuona kweDaan genetic bvunzo yaive yakangofanana neiyo yeCRS. Izvi zvinowirirana neyekufunda jaya jawu kuitiswa kuAnhui University muHuinan, China, uye iyo yekugadzira yemugadziri ye100% Chibvumirano chakanaka. Pasinei neshumo yemhedzisiro inoshandirwa, imwe muenzaniso yaive yenhema dzisina kunaka mushure mekuita kuti uenderane neyakafanana neye Abboro sers-cov-2 uye surure biotech ncov-2019 ssays. Izvi zvinoratidza kuti panogona kunge paine kusiyana mumhedzisiro yemhando dzakasiyana dzemigwagwa. Zvakangodaro, muchidzidzo chakaitwa kuChina15, mhedzisiro yeDaan gen Assay yaive yakasiyana zvakanyanya (P <0.05) zvichienzaniswa neyekucherekedzwa kweiyo lab-yakatsanangurwa rezita. Zvakangodaro, muchidzidzo chakaitwa kuChina15, mhedzisiro yeDaan gen Assay yaive yakasiyana zvakanyanya (P <0.05) zvichienzaniswa neyekucherekedzwa kweiyo lab-yakatsanangurwa rezita. Тем не менее, в иследени, результа DA wash а анализа. Nekudaro, mune chidzidzo kuChina15, Daan gene queiss mhedzisiro yaive yakasiyana zvakanyanya (P <0.05) kubva kune yavo yekurabhamba yekuzivisa.然而, 在中国进行的研究中 15, 大安基因检测的结果与其实验室定义的参考检测相比有显着差异 (P <0.05).然而, 在中国进行的研究中 15, 大安基因检测的结果与其实验室定义的参考检测相比有显着差 <0.05 Однако и исследени, резултаты генетискогогоча Daan набораторн. Nekudaro, mune chidzidzo kuChina15, mhedzisiro yechiitiko cheDaan's bvunzo zvaive zvakasiyana (P <0.05) tichienzanisa neyekutaura kwaro laboratori.Uku kusiyana kunogona kuve nekuda kwekunzwa kwekunzwa kwemuedzo wekuteerera kuwongorora-cov-2, uye zvimwe zvidzidzo zvinogona kuve zvakakosha kuti uone chikonzero.
Uyezve, kudzidza kwedu kwakaongorora maitiro ekufananidza-cov-2 bgi kuganhurwa ). = 98.8%). Cohen's kappa tsika yakaratidza chibvumirano chakanaka (K = 0.975). Zvidzidzo muNetherlands16 ne china115 zvakaratidza zvisingaradzanise mhedzisiro. Iyo Sars-COV-2 BGI Test igini imwe chete (Orf1a / b) Kuongororwa bvunzo uchishandisa 10 μl kukwirisa / kuwanikwa kwegweki. Pasinei nekubvumirana kwakanaka kwehurumende nemabasa edu, kuongororwa kwakarasikirwa neshumiro mbiri dzakanaka (1.22%) yeiyo yakazara sampuli. Izvi zvinogona kuve nekiriniki yakakura zvekutumira zvine simba kune vese vane moyo murefu uye munharaunda mazinga.
Imwe ongororo yekufananidza inosanganisirwa muchidzidzo ichi yaive surure ye biotech ncov-2019 rrt-pcr (ruo) assay; iyo yakazara matchester muzana yaive 96.3%. Simba reCentthi rakatemerwawo neCocpa's kapppa's kappeta kukosha, yaive 0.925, inoratidza chibvumirano chizere neCRS. Zvekare, mhedzisiro yedu yakafanana neyezvidzidzo zvakaitwa kuCentral South University muChangsha, China, uye kuClinical Laboratory Chipatara cheLiuuzhou, Liuuzhou Guta, China17. Kunyangwe iyo yepamusoro yepamusoro manhamba concordance yakanyorwa, iyo chi-chi-chidiki bvunzo (macnemar bvunzo) zvakaratidza kuti mhedzisiro yeiyo Biotech yakasarudzika yakaenzana neCRS (P <0.005). Kunyangwe iyo yepamusoro yepamusoro manhamba concordance yakanyorwa, iyo chi-chi-chidiki bvunzo (macnemar bvunzo) zvakaratidza kuti mhedzisiro yeiyo Biotech yakasarudzika yakaenzana neCRS (P <0.005). Несмотря наря нари зазкикиканананаванаванаванава со ли, ли поко результатататата Kunyangwe iyo yakanaka statisticle chibvumirano pamusoro yakanyorwa, iyo chi-mraturedzo bvunzo (mcnemar bvunzo) yakaratidza kuti mhedzisiro yeiyo svutugadzike yakakoshwa nemusiyano wakaenzaniswa neCRS (P <0.005).尽管记录了上述良好的统计一致性, 但卡方检验 (Macnemar 检验) 表明, Surure Biotech 【Crs 相比具有统计学显着差异 (P <0.005).尽管 记录 了 上述 良好 的 一致性, 但 检验 ((Macnemar 检验,, Surure Biotech 检测 与 与 Crs 相比 具有 (P <0.005 .........)))) Несмотря на не оыше ворошее вое сое (квари с и, к раазницу (p <0,005) межжд анизом surure biotech и crs. Pasinei nechibvumirano chakanaka chechibvumirano chakanyorwa pamusoro, chi-chi-chi-mrass test (mcnemar bvunzo) yakaratidza mutsauko wakakoshaSamples matanhatu (3.66%) yakawanikwa kuti ive yenhema dzisingaenzaniswi neCRS (Supplementary tafura 1); Izvi zvakakosha, kunyanya kupihwa masimba ekutapurirana nehutachiona. Iyo data iri pamusoro zvakare inotsigira iyi yakaderera yekuona rate115.
Muchidzidzo ichi, CT eCT zvakatsanangurwa nePlatferifomu yeumwe neumwe, neiyo yakaderera zvinoreva CT kukosha kwakataurwa muAbbott sers-cov-2 assay. Mhedzisiro iyi inogona kuve yakanangana naAbbott's panguva imwe chete yakasanganiswa genetic yekuedza system yekuonekwa kweSers-Cov-2. Naizvozvo, maererano nemufananidzo 1, 87.6% yeAbbott sars-cov-2 mhedzisiro yaive neCT kukosha pazasi makumi maviri CT kukosha pamusoro makumi matatu hazvina kunyorwa. Pamusoro pekushandiswa kwa Abbott weSurs-COV-2 PANEL Kuedza Kuedza, mhedzisiro iyi inogona kuongororwa / ml) ML) 19.
Chidzidzo ichi chine zvimwe zvevengo: Chekutanga, isu hatina chiyero / nzira dzakadai sedzakaruki kana mamwe mimwe testory kana imwe bvunzo dzekutengesa (LARATION TESS (LLA)] Nekuda kwekushayikwa kwezvinhu. Chechipiri, mafungidziro aya anoshandiswa mune ino Nasaopharysyaal Swabs, nepo mhedzisiro yacho yakanga isingaonekwe kune mamwe marudzi ekufungidzira, uye chechitatu, saizi yedu yemuenzaniso yaive idiki.
Ichi chidzidzo chakafananidzwa nekuita kwemavheni mana rrt-pcr assays kune mapfumbamwe-cov-2 uchishandisa NASOPHARYRESRIAL Samples. Zvese zvekuona fungidziro zvaive zvakaringana kuita, kunze kwekusimbisa kweiyo biotech assay. Kunze kwezvo, iyo yakaderera positivity rate yakazivikanwa muSansure Biotech Assay Ensay ichienzaniswa neCRS (P <0.05). Kunze kwezvo, iyo yakaderera positivity rate yakazivikanwa muSansure Biotech Assay Ensay ichienzaniswa neCRS (P <0.05). Кроме то, в теттте simbisai bionech прынвлен выи Uye zvakare, iyo surure yeBiotech bvunzo yakaratidza yakaderera muzana yemhedzisiro yakanaka uchienzaniswa neCRS (P <0.05).此外, 与 Crs 相比, Surure Biotech 检测的阳性率较低 (P <0.05).此外, 与 Crs 相比, Surure Biotech 检测的阳性率较低 (P <0.05). Ароме то, наназ иotech имень половитеуть презультани по савнению ю crs (p <0,05). Uye zvakare, iyo surure biotech assay yaive neyakaderera positivity chiyero ichienzaniswa neCRS (P <0.05).Iyo Surure Biotech NCOV-2019 (Ruo) kuongororwa kwePPA, NPA uye Kubvumirana kwechibvumirano chakapfuura 93.5% neCohen Kappa Simba reContless kukosha kwe10925. Pakupedzisira, iyo surure yeBiotech Assay (Ruo) inoda kuenderera mberi kwechiitiko chekushandisa muEthiopiya, uye nekuwedzera tsvakiridzo inofanirwa kutariswa kuti inoongorora zvirevo kubva kune vagadziri.
Kuenzanisa kwekufunda kwakaitwa pazvivakwa zvina zvehutano muAddis Ababa, EKA Kotebe Chipatara, Milenene Chipatara Center, Zedched muchipatara yeZewed Iyo data yakaunganidzwa pakati paZvita 1 ne 31, 20, 2020. Zvivakwa zvekurapa zvekudzidza izvi zvakavezwa zvichienderana nenhamba yavo yepamusoro uye kuwanikwa kwevanhu vazhinji vepamusoro muguta. Saizvozvo, zviridzwa, kusanganisira iyo Abhi 7500 uye Abbott M2000 chaiyo-nguva PCR zviridzwa, uye ina PRC gadziriro yeNar Reagent yechiitiko ichi, semarabhorati muItiopiya anoshandisa angangoita mana acho. Genekera, Abbott Sars-Cov-2 bvunzo, surure Biotech bvunzo, uye sars-cov-2 bgi bvunzo yakaitwa panguva yekudzidza).
Kuedza kweSurs-COV-2 yakaitwa kubva ku1 kusvika ku10 Zvita 2020 ichishandisa 3 ml yeVIR yekutakura pakati (VTM), Shenzhen, China) kubva kune vanoongorora Nasopharysya Sampuli Sampuli akaunganidzwa nekudzidziswa kwemuenzaniso vateresi uye vakatumira kuEPhi mumapepa matatu. Asati asati azviparadzanise pasina, sampu imwe neimwe inopihwa nhamba yakasarudzika yekuzivikanwa. Kubvisa kunoitwa kubva kune yega yega sampula pakarepo pakusvika uchishandisa manyowani uye otomatiki ekubvisa nzira. Nekudaro, kune otomatiki yekubvisa Abbott m2000, 1.3 ml (inosanganisira 0.5 ml yakawedzerwa mubatanidzwa wetsiva (yebbott mel. ) Batch ye96 [samples, maviri ekuona masampuji uye maviri ekutonga kumigoka. Saizvozvo, kune zvibodzwa zvebhuku, shandisa iwo mamwe samples (ye otomatiki yekubvisa uye kuwanikwa). Saka, mukati memugadzirisa, 140 μL samples dzaive dzakapetwa uye dzakabviswa uchishandisa QIAamp VIRIRA RNA KIT (HIGEN GGHI KIG Nemaoko anobviswa eluates akasungirirwa uye akaonekwa achishandisa Abi 6.00 Thermal Cyling achishandisa Sers-COV Liay, Daan lefay, uye surure Biotech assay.
Kuzviparadzanisa otomatiki uye kucheneswa kweSers-COV-2 VIRIRA RNA Inotevera Magnetic BEAD Simba uchishandisa Abbott Sampu Ekugadziriswa Regral Regent Inactivation yemasampula uye solubilization yehutachiona hwehutachiona ichiitwa uchishandisa decgent ine Guanadine Iyo rna yakabva yaparadzaniswa neProtein neSolid Spaspation Inoshandisa Silica Nhanho yekukwira inobvisa dzinosara mapuroteni uye marara kuti ubudise mhinduro yakajeka. Pachena rna iri yega kubva kuSilica-yakavakirwa microparticles ichishandisa chiridzwa chemagineti yemushini20,21. Kune rimwe divi, bhuku rekuzviparadzaniswa uye kucheneswa kweRNA rinoitwa neiyo spin column nzira uchishandisa centrifugation pachinzvimbo chemagineti uye kupatsanurwa kwe microparticles kubva kune iyo microparticles kubva kune iyo
Iyo Abbott chaiyo-yenguva inochengetedza-cov-2 yekuona bvunzo (abbott molecular, Inc.) yakaitwa maererano nemirairo yemugadziri, iyo yakagamuchira eua19,22 kubva kune uyo uye fda. Mune ino protocol, sampuli yekushandisa isati yaitwa mubhati remvura pa56 ° C kwemakumi matatu emaminitsi makumi matatu. Mushure mekunge vatiramire vevatirivo, nuclec acid yekubvisa pane abbot m2000 SP chiridzwa kubva ku0,5 ml VTM ichishandisa ABBORT M2000 Sampuji yekugadzirira system yekugadzirira zvinoenderana nemugadziri. Kugadzirwa uye kuongororwa kwakaitwa uchishandisa Abbott M2000 RT-PCR chiridzwa, uye dual yekuona yakaitwa yeRDRP neNGENY. Rox) uye VIC P (Proprietary Dye) Yekutarisirwa uye Kuonekwa Kwemukati Kudzora, Kubvumira Kuongororwa Panguva imwe chete yekugadzira zvigadzirwa 19.
Iyo Amplification yekutsvaga nzira yeiyi kit inoenderana neyimwe-nhanho rt-pcr texology. Iyo orf1a / b uye n majini yakasarudzwa seyakachengetedzwa matunhu ne daan gene tekinoroji kuti uone chinangwa cheDunhu. Chaizvoizvo primers uye fluorescent probes ( Iyo yekupedzisira ine mishonga uye tenzi mishoni yakagadzirirwa nekuwedzera 5 μl ye leuent kusvika makumi maviri emasisitimu musanganiswa weThe masista kusvika kune yekupedzisira vhoriyamu ye25 μl. Kukwidziridzwa uye kuwanikwa kwakaitwa panguva imwe chete pane absi 750024 chaiyo-nguva pcr Boatment.
Iyo orf1a / b uye n ma rini yakaonekwa uchishandisa iyo surure yeBiotech ncov-2019 nucleic acid diagnostic kit (fluorescent pcr kuwanikwa). Gadzirira chaiyo probes kune yega yega chinangwa cheGex nekusarudza iyo Fam chiteshi yeiyo orf1a / b dunhu uye iyo rox chiteshi che n gene. Kune iyi lefaay kit, leuent uye tenzi sanganisa reagents anowedzerwa seinotevera: gadzirira 30 μl Master musanganiswa uye 20 μl yakasimba sampuli yekuona / kukwidziridzwa. Chaiyo-nguva PCR abi 750025 yaishandiswa kukwikwidza / kuwanikwa.
Iyo inopinda-cov-2 bgi bvunzo ndeye fluorescent chaiyo-nguva rr-pcr kit yekuongororwa kweiyo cabid-19. Dunhu renzvimbo iri mune orf1a / bunhu / bunhu reSurs-Cov-2 genome, iyo iri imwe nzira yekuona yakanyorwa. Mukuwedzera, iyo Housekeching vanhu jee jee β-Actin ndeyemukati inotungamirwa chinangwa cheGene. Iyo tenzi musanganiswa yakagadzirirwa nekusanganisa 20 Abi 7500 Fluorescent huwandu chaihwo-nguva PCR chiridzwa yaishandiswa kuumbwa uye kuwanikwa. All Nucleic acid kukwikwidza, PCR MAM urimo kune imwe neimwe learsay, uye kududzira kwemhedzisiro kwakaitwa zvinoenderana nemirairo yemugadziri (tafura 3).
Mukuongorora uku kuongorora, hatina kushandisa iyo Reference nzira kuti tizive chibvumirano (chakanaka, chisina kunaka, uye chakawandisa) uye kumwe kuenzanisa ma parmeter kune mana kuongorora. Kuenzanisa kwega kwega kwakaitwa neCRS, muchidzidzo ichi iyo crs yakaiswa nemutemo "chero yakanaka" uye mhedzisiro yacho yakanga yakatemwa, kwete bvunzo imwe chete, isu takashandisa kanenge kaviri miedzo yebvunzo. Mukuwedzera, mune imwe nyaya yeCOVid-19 kutapurirana, mhedzisiro dzenhema dzine njodzi kupfuura mhinduro dzenhema. Naizvozvo, kutaura kuti "zvakanaka" sezvinobvira sezvinobvira kubva kuCRS zvinoitika, kanokwana maviri leffy miedzo inofanira kuve yakanaka, zvinoreva kuti imwe chete yakanaka mhedzisiro inogona kubva kuEUUsay. Saka, kubva pamhedzisiro ina bvunzo, mikana miviri kana anopfuura emhedzisiro inopa mhedzisiro yakafanana inoonekwa sechokwadi kana yakaipa18,27.
Dhata yakaunganidzwa uchishandisa yakarongedzwa data yekubvisa mafomu, yekupinda kwedata uye kuongororwa kwakaitwa uchishandisa Excel Stands uye Spss shanduro 23.0 yeiyo inotsanangudza nhamba. Chinhu chakanaka, chisina kunaka, uye zvakazara chikamu chibvumirano chakaongororwa, uye chikero chekappa chakashandiswa kuona iyo degree rechibvumirano cheimwe neimwe nzira neCRS. Kappa
Tsika yekubvumidzwa yakawanikwa kubva kuYunivhesiti yeAddis Ababa uye ese maProtocol kuti idzidze iyi yakatenderwa nehutano hweEtiopiya hweEtisheni Nhamba yereferensi yeiyo EPHI ETICICS License ndeye EPHO / IRB-279-2020. Nzira dzese dzakashandiswa zvinoenderana nekurudziro uye zvigadziriso zveiyo Etiopian yakakwana mirayiridzo yekurapa kwekurapa kweiyo cavid-19. Mukuwedzera, mvumo yakanyorwa yakanyorwa yakawanikwa kubva kune vese vanodzidza vatori vechikamu vasati vatora chikamu muchidzidzo.
Yese data yakawanikwa kana kuongororwa muchidzidzo ichi inosanganisirwa mune ino chinyorwa chakabudiswa. Dhata inotsigira mhedzisiro yeiyi ongororo inowanikwa kubva kumunyori weruremekedzo pane chikumbiro chine musoro.
Sangano Rinoona nezve Utano Pasi pose. Kurudziro yemarabhoritori kuyedzwa mazano eCidid-19: Interim Nhungamiro, Kurume 21, 2010 Kwete / 2019-NCOV / LAB_TING / 2020.1 (Ndiani, 2020.1 (Who, 2020.1 (Who
Mouliou, DS, Pantazopoulos, I. & Gourgoulianis, ki covid-19 smart yekuongorora muDhipatimendi reMergency. Mouliou, DS, Pantazopoulos, I. & Gourgoulianis, ki covid-19 smart yekuongorora muDhipatimendi reMergency.Muliou, DS, pantazopoulos, ini. Uye gurgulianis, ki yakachena kugona kweiyo comid-19 muDhipatimendi reMergency: Zvese zviri muitiro.Muliou Ds, pantazoupoupolos I. Uye gurgulyanis ki ngwangisi kuongororwa kweiyo comid-19 mumakwenzi emergency: Ekupedzisira-kupedzisa kuwirirana mukuita. Nyanzvi Reverend Respire. mushonga. 3, 263-272 (2022).
Mitchell, SL & St George, K. Kuongororwa kweCovid19 ID ikozvino EUSASAY. Mitchell, SL & St George, K. Kuongororwa kweCovid19 ID ikozvino EUSASAY.Mitchell, Sl uye St. George, K. Kuongorora kweCovid19 ID ikozvino EUSASAY.Mitchell Sl uye St. George K. Kuongororwa kweCovid19 id izvozvi eua assay. J. Clinical. Utachiona. 128, 104429. Https://4doi.org/10.1016/j.jccv.2020.104429 (2020).
WHO. Laboratory kuona chirwere cheCoronavirus 2019 (chovid-19) muchirwere chevanhu. https://www.www.ww.int/Publication/I/item/140665-331501 (inowanikwa 15 Nyamavhuvhu 2020) (ndiani, 2020).
UDugama, B. ET Al. Chand-19 Kuongororwa: Zvirwere uye Kuedza Zvishandiso. Acs Nano 14 (4), 3822-3835 (2020).
Syed S. et Al. Kugadzwa kwekoreji yePathologists yeEast, Central uye Southern Africa - Chikoro cheSouth Forhology yeMiddle East neSouth Africa. Africa. J. Lab. mushonga. 9 (1), 1-8 (2020).
Itiopian Intitute yehutano hweveruzhinji, hushumiro hwehurumende yehutano. Interim National Strategy uye nhungamiro yekuongororwa kwerabhoritari yekuongororwa kweiyo Chand-19. https::epig.gov.et/images/conoc_phed-19_Covid-19_Covid-4diagnosis_eng.pdf (SANG.)
Woloshin, S., Patel, N. & Kesselheim, semiedzo isina kunaka yeCV-COV-2 Zvishamo Zvinonetsa uye Zvinorehwa. Woloshin, S., Patel, N. & Kesselheim, semiedzo isina kunaka yeCV-COV-2 Zvishamo Zvinonetsa uye Zvinorehwa.Voloshin S., Patel N. Uye Kesselheim semiedzo yenhema-isina kunaka yeanogara-cov-2 hutachiona uye nemhedzisiro yavo.Voloshin S., Patel N. Uye Kesselheim semiedzo yenhema yekutsamwiswa uye nekukanganiswa kweanopinda-cov-2 utachiona. N.E eng. J. Mushonga. 383 (6), e38 (2020).
Mouliou, DS & Gourgoulianis, ki yenhema-yakanaka uye enhema-isina kunaka comid-19 kesi yekudzivirira uye nzira dzekutonga, dzimba dzekudzivirira, uye kuwedzera. Mouliou, DS & Gourgoulianis, ki yenhema-yakanaka uye enhema-isina kunaka comid-19 kesi yekudzivirira uye nzira dzekutonga, dzimba dzekudzivirira, uye kuwedzera. Mouliou, DS & Gourgoulianis, Ki ложнотьльные и ложнотеле-19: респиратео дальнейшие перспективы. Mouliou, DS & Gourgoulianis, ki Nhema dzakanaka uye dzenhema zviitiko zveCIVid-19: Maitiro ekuramba uye ekurapa, kushandira uye nzira yekuenda kumberi.Muliu, DS uye Gurgulianis, ki yenhema, nyaya dzenhema-dzenhema dzeChandd-19: Nzira dzekudzivirira kwekufema uye kurapwa, kurapwa uye nenzira yekuenda kumberi. Nyanzvi Reverend Respire. mushonga. 15 (8), 993-1002 (2021).
Mouliou, DS, Ioannis, P. & Konstantinos, G. COVid-19 Kuongororwa muDhipatimendi reMergency: Kuona muti asi kurasikirwa nesango. Mouliou, DS, Ioannis, P. & Konstantinos, G. COVid-19 Kuongororwa muDhipatimendi reMergency: Kuona muti asi kurasikirwa nesango.Mouliou, DS, Ioannis, P. naKonsntinos, G. COVid-19 Kuongororwa muDhipatimendi reMergency. Ona muti, kurasikirwa nesango.Muliou Ds, Ioannis P., uye Konstantinos G. COVID-19 Kuongororwa Mumakamuri Ekukurumidzira: isina sango rakaringana remiti. Kuoneka. mushonga. J https://doii.org/10.1136/emericmeds1021-212219 (2022).
Degli-Angeli, E. ET Al. Kubvumidzwa uye kusimbiswa kwekuongorora kwekuongorora uye kwekiriniki kweAbbott Realtime Sars-Cov-2 Assay. J. Clinical. Utachiona. 129, 104474. Https://4doi.org/10.1016/jvcc.2020.104474 (2020).
Mollaei, Hr, Afshar, Aa, Kalantar-Neyestanaki, M. & Aflatokuan, B. Kufananidza Shanu Prever Dunhu reVatiki-19 Kuonekwa kwehutachiona hwehutachiona hwehutachiona Mollaei, Hr, Afshar, Aa, Kalantar-Neyestankai, M. & Aflatotoan, B. Kuenzanisa Kwemashanu PradMollaei, Hr, Hr, Afshar, Aa, Kalantar-Neyestanaki, M. Uye kufananidza kwemakumi mashanu ezvikamu zvechivhi Mollaei, Hr, Hr, Afshar, Aa, Kalantar-Neyestanaki, D. & Aflatatoan, B. 比较来自 CRD-19 不同基因组区域的五个引物组, 用于通过常规 rt-pcr 检测病毒感染. Mollaei, Hr, Afshar, Aa, Kalantar-Neyestankai, M. & Aflatatour, B. Kuenzanisa kwe5 genetic Matunhu eCovic-19 yekuonekwa kwehutachiona hwehutachiona hwert-pcr.Mollaei HR, AFSHAR AA, Kalantar-Neyestanaki D, Fazlalipour M. Uye Aflalipour M. Uye kuenzanisa kwemakumi mashanu emitambo kubva kumatunhu akasiyana-siyana ehutachiona hwehutachionaIran. J. Microbiology. 12 (3), 185 (2020).
Goesterz, I. ET Al. Mhedzisiro yekutanga yeiyo nyika yekuongorora yemhando yekuongorora kwehurongwa hwekuonekwa kweSers-COV-2 genome kutevedzana. J. Clinical. Utachiona. 129, 104537. Https://toiiii.org/10.1016/jccv.2020.104537 (2020).
Wang, M. et Al. Ongorora kuongororwa kwekushanda kweshanu yert-pl-pl-pl-pl-pl-pl-pits yeakakomba ekufemesa ekufema syndreme coronavirus 2. J. clinical. Laboratori. anus. 35 (1), E23643 (2021).
Wang B. et al. Kuongororwa kweanomwe wekutengeserana anowanikwa kiriniki. Kemikari. Laboratori. mushonga. 58 (9), e149-e153 (2020).
van casterren, pb et al. Kuenzanisa kweanomwe yekutengeserana rt-pcr codhid-19 idzo diagnostic kits. J. Clinical. Utachiona. 128, 104412 (2020).
Lu, Yu, et Al. Kuenzanisa kwekufungidzira kwekuongorora kweiyo mbiri plcr kits yekuonekwa kweanopinda-cov-2 nuclic acids. J. Clinical. Laboratori. Anus. 34 (10), e23554 (2020).
Lefart, pr, etc. Kaira yekufananidza yevanoita mana-cov-2 nucleic acid leading kuongororwa. Microbiology. Kukanganisa. diss. 99 (1), 115200 (2021).
Abbott Molecule. Abbott chaiyo-nguva sars-cov-2 ongororo package isa. https://www.molecular.abbott/us/Products/Infet-Disease/realisee-6V 1-12. (Kubva muna Nyamavhuvhu 10, 2020) (2020).
Klein, s. et al. Sars-COV-2 rna yekuzviparadzanisa uchishandisa magineti ekukurumidzira lead-scale yekuona neRT-QPCR uye RT-RAMP. Virus 12 (8), 863 (2020).